Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. Lung cancer - the facts
4. Lung cancer will be the 5th biggest killer by 2020
5. Existing imaging technologies
6. Cancer detection on spiral CT - clinical studies
7. The I-ELCAP study
8. Detection rate: breast vs. lung cancer
9. The platinum microcoil treatment method
10. Resection using platinum microcoils and CT
11. National lung cancer screening trial (USA)
12. The NELSON trial
13. Multi-slice thoracic spiral CT
14. Size of CT detected lung nodules
15. Pulmonary nodules
16. Implication of positive screen
17. Suspicious lesions
18. Positive PET scans in screening setting
19. Enlarging lesions - images
20. PET results for enlarging lesions
21. Implication of new nodule on annual repeat scan
22. Skewed cell types with spiral CT screening alone
23. BCCA lung health study
24. Bimodality lung cancer screening
25. Complementary screening technologies
26. Autofluorescence bronchoscopy
27. Autofluorescence spectra
28. Mechanism of decreased fluorescence in tumors
29. Fluorescence-reflectance imaging
30. Early lung cancer detection by autofluorescence
31. Localization of dysplasia and carcinoma in-situ
32. Quantitative imaging improves specificity
33. Optical coherence tomography
34. OCT image of normal epithelium
35. OCT image of metaplasia
36. OCT image of moderate dysplasia
37. OCT image of severe dysplasia
38. OCT image of carcinoma in-situ
39. OCT image of invasive carcinoma with BM loss
40. Carcinoma in-situ left main bronchus
41. OCT imaging of abnormal fluorescence in LMB
42. OCT image of LMB
43. Simple effective endoscopic therapy for carcinoma
44. Carcinoma in-situ 5 years follow-up
45. Genes distinguish smokers with or without cancer
46. Why not screen all smokers?
47. Variations in lung cancer risk among smokers
48. Early detection biomarkers
49. Biomarkers
50. Detection of lung cancer using serum biomarkers
51. Framingham CVD risk assessment model
52. Lung cancer risk assessment model (1)
53. Validation of modified PLCO model
54. Lung cancer risk assessment model (2)
55. Lung function as a biomarker for gender differences
56. Risk prediction using PLCO model+ lung function
57. ROC curve with all markers
58. An open framework prediction model
59. Cost of test and adoption
60. Summary
61. Comprehensive lung cancer control program
62. Acknowledgements

Topics Covered

• Lung cancer is the most common cause of cancer death world-wide
• Detecting and treating the disease early is the most promising approach to improve the outcome of patients with lung cancer
• Strengths and limitations of current early detection technologies
• Lung cancer risk prediction models to select individuals at high risk for lung cancer

Links

Series:

• Cancer Therapy

Categories:

• Cancer
• Clinical Practice
• Methods

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on January 6, 2009

Financial Disclosures

• Prof. Stephen Lam has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.